石三军
一、个人简介
石三军，教授、博士生导师。哈佛大学留学归国，四川省中医药管理局学术和技术带头人和四川省学术和技术带头人后备人选、省部级优秀人才计划入选者、四川省特聘专家、四川省杰青、省级创新创业优秀指导教师等；致力于传统脂质材料、新型安全材料在核酸蛋白药物及中药活性分子递释上的应用基础研究，其中开发的超分子复合物技术包载核酸药物被多位美韩科学家评价为首次研究报道。相关成果以第一或通讯作者身份在angew chem int edit, nano today, j control release, acta pharmaceutica sinica b等顶级杂志上发表sci论文多篇，最高影响因子19，参编《药剂学》和英文专著各1项，授权专利1项；先后主持了国家科技重大专项（726万）、国家自然科学基金等项目8项，累计经费1000余万元；成果先后获得重庆市科技进步二等奖、四川省科学技术进步三等奖、重庆市科协自然科学优秀学术论文，以及int j biol macromol评审“杰出贡献奖”等奖项；指导学生获得“互联网 ”创新创业竞赛国家级奖励2项、“挑战杯”大学生创业大赛国家级铜奖及“创青春”中国青年创新创业大赛铜奖，以及部省级创新创业奖励10余项；同时担任了本学科著名sci期刊curr pharm design客座主编、evid based complement alternat med编委、journal of pharmaceutical analysis (if=14)青年编委、frontiers in pharmacology、frontiers in oncology客座编辑、smartmat青年编委、《现代肿瘤医学》编委，并任世中联肿瘤精准医学专委会常务理事、中华中医药学会中成药分会委员、省科青联理事、省药学会药剂专委会委员等职务。
二、代表性成果
1.dandan mi, jiaojiao li, rujing wang, yuke li, lan zou, chen sun, shenao yan, huan yang, mengnan zhao*, sanjun shi*. postsurgical wound management and prevention of triple-negative breast cancer recurrence with a pryoptosis-inducing, photopolymerizable hydrogel. journal of controlled release, 2023. (if=11.467)
2.mengnan zhao, rujing wang, kunmeng yang, yuhong jiang*, yachen peng, yuke li, zhen zhang, jianxun ding*, sanjun shi*. nucleic acid nanoassembly-enhanced rna therapeutics and diagnosis. acta pharmaceutica sinica b, 2022. (if=14.9)
3.yao chen, jiru yang, yi zuo, chaozheng zhang, yiru pu, qingren, xiaoli, yunqian huang, hui huang, huanyang, ouyan you, xila xia, aiping lu, sanjun shi*, yun deng*, jun lu*. voacamine is a novel inhibitor of egfr exerting oncogenic activity against colorectal cancer through the mitochondrial pathway. pharmacological research, 2022; 184: 106415. (if=10.334)
4.yan chen, rui zhang, dandan mi, qiuju wang, tingwenli huang, xinwei dong, hongwei zhang, hongtao xiao, sanjun shi*. spk1/s1p axis confers gastrointestinal stromal tumors (gists) resistance of imatinib. gastric cancer, 2023; 26: 26-43. (if=7.7)
5.mengnan zhao, dandan mi, bijan emiliano ferdows, yuke li, rujing wang, jiaojiao li, dylan patel, sanjun shi*, wei tao*. state-of-the-art nanotechnologies for the detection, recovery, analysis and elimination of blood-based biosources in cancer liquid biopsy. nano today, 2022; 42: 101361. (if=18.962)
6.hanmei li, qi tang, yao wang, mao li, yannan wang, hong zhu, fang geng, di wu, lianxin peng, gang zhao, liang zou, sanjun shi*. injectable thermosensitive lipo-hydrogels loaded with ropivacaine for prolonging local anesthesia. international journal of pharmaceutics, 2021; 121291. (if=6.5)
7.hong wang, yu zheng, qiang sun, zhen zhang, mengnan zhao, cheng peng*, sanjun shi*. ginsenosides emerging as both bifunctional drugs and nanocarriers for enhanced antitumor therapies. journal of nanobiotechnology, 2021; 19: 322. (if=9.43)
8.sanjun shi*, wenliang li. cancer stem cell based targeted therapy. current pharmaceutical design, 2020; 26(17): 1951. (if=3. 3)
9.xili lu#, sanjun shi#, hanmei li, ethan gerhard, zhihui lu, xinyu tan, wenliang li, kevin m.rahn, denghui xie, guodong xu, fang zou, xiaochun bai, jinshan guo, jian yang. magnesium oxide-crosslinked low-swelling citrate-based mussel-inspired tissue adhesives. biomaterials, 2020; 232: 119719. (if=15.3)
10.lili wei, chenyuan wang, xianjue chen, bing yang, kun shi, leah r. benington, lee yong lim, sanjun shi*, jingxin mo*. dual-responsive, methotrexate-loaded, ascorbic acid-derived micelles inhibit nf-κb signaling to exert anti-tumor and anti-metastasis effects in an orthotopic mouse model of human choriocarcinoma. theranostics, 2019; 9(15): 4354-4374. (if=11.6)
11.sanjun shi, na kong, chan feng, aram shajii, claire bejgrowicz, wei tao*, omid c. farokhzad*. drug delivery strategies for the treatment of metabolic diseases. advanced healthcare materials, 2019, 1801655. (if=11.1)
12.yuanyuan li#, sanjun shi#, yue ming, linli wang, chenwen li, minghe luo, ziwei li, bin li, jianhong chen. specific cancer stem cell-therapy by albumin nanoparticles functionalized with cd44-mediated targeting. journal of nanobiotechnology, 2018; 16: 99. (if=9.4)
13.minghe luo, yue ming, linli wang, yuanyuan li, bin li, jianhong chen, sanjun shi*. local delivery of deep marine fungus-derived equisetin from polyvinylpyrrolidone (pvp) nanofibers for anti-mrsa activity. chemical engineering journal, 2018; 350: 157-163. (if=16.7)
14.sanjun shi, likai yang, qiu’e yao, xin li, yue ming, yu zhao. ascorbic palmitate as a bifunctional drug and nanocarrier of paclitaxel for synergistic anti-tumor therapy. journal of biomedical nanotechnology, 2018; 14: 1601-1612. (if=3.64)
15.sanjun shi, yuanyuan li, yue ming, chenwen li, ziwei li, jianhong chen and minghe luo*. biological activity and chemical composition of the endophytic fungus fusarium sp. tp-g1 obtained from the root of dendrobium officinale kimura et migo. records of natural products, 2018; 12(6): 549-556. (if=2)
16.min zhou, xin li, yuanyuan li, qiu’e yao, yue ming, ziwei li, laichun lu, sanjun shi*. ascorbyl palmitate-incorporated paclitaxel-loaded composite nanoparticles for synergistic anti-tumoral therapy. drug delivery, 2017; 24: 1230-1242. (if=6.82)
17.hanmei li, tao liu, yuxuan zhu, qiang fu, wanxia wu, jie deng, li lan, sanjun shi*. an in situ-forming phospholipid-based phase transition gel prolongs the duration of local anesthesia for ropivacaine with minimal toxicity. acta biomaterialia, 2017; 58, 136-145. (if=10.63)
18.sanjun shi*, min zhou, xin li, et. al. synergistic active targeting of dually integrin αvβ3/cd44-targeted nanoparticles to b16f10 tumors located at different sitxes of mouse bodies. j control release, 2016; 235: 1-13. (jcr1区，if=11.47)
19.sanjun shi, lu han, tao gong, zhirong zhang, xun sun. systemic delivery of microrna-34a for cancer stem cell therapy. angew chem int edit, 2013; 52(14): 3901-3905. (if=16.82)
20.sanjun shi, lu han, li deng, yanling zhang, hongxin shen, tao gong, zhirong zhang, xun sun. dual drugs (microrna-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. j control release, 2014; 194(28): 228-237. (if=11.47)
m6米乐安卓版下载的联系方式：
成都中医药大学科技楼西耳房1楼
email：shisanjuns@163.com
欢迎具有药学、中药学、临床医学、化学、高分子材料科学或者生物科学等相关背景的同学加入课题组！